National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

multikinase inhibitor BAY 73-4506
An orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Multikinase inhibitor BAY 73-4506 binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:BAY 73-4506



Previous:MUC1-KLH conjugate vaccine, MUC1-KLH vaccine/QS21, Mucomyst, multi-epitope melanoma peptide vaccine, MultiHance
Next:MultiStem, multitargeted receptor tyrosine kinase inhibitor ABT-869, multitargeted receptor tyrosine kinase inhibitor MP470, multitargeted tyrosine kinase inhibitor AP24534, multitargeted tyrosine kinase inhibitor JNJ-26483327

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov